Stepping into the fast-paced world of Ventures Accelerated, three new recruits : Wendy Boakai, Iñigo de Yturriaga Melgarejo and Ombeline Ragoucy are already making their mark. Fresh perspectives, bold ambitions, and a shared drive to innovate: this is the energy they bring to the team.

Meet Dr. Roger Lias, one of our Accelerators with a career spanning biopharma, CDMOs, and advisory roles across Europe, North America, and Asia. He brings a deeply entrepreneurial mindset to building and scaling life science companies.

Amongst the key voices at this year’s JPM Healthcare Conference in San Francisco was Ulf Hannelius, CEO of Diamyd Medical, who arrived with a clear strategic mission: preparing the global investment community for a potential paradign shift in the treatment of type 1 diabetes.

A new collaboration between OnDosis and Diamond Therapeutics aims to enable accurate, reproducible dosing in low-dose psilocybin research, supporting a Phase 2a study in generalized anxiety disorder.

Diamyd Medical has strengthened its manufacturing collaborations in Sweden through a long-term partnership with APL and a new strategic alliance with NorthX Biologics, supporting controlled scale-up and future commercialization in biologics.

Against the high-stakes backdrop of the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco in January 2026, OnDosis CEO Martin Olovsson reveals how a decade of rigorous preparation and an "iPad-style" approach to precision dosing are paving the way for a major U.S. launch.

What does it mean to lead with purpose in life science? We sat down with Johanna Bergh, Business Area Manager for Life Science at AWA, to talk about intellectual property, global collaboration, and why supporting initiatives like the Swedish–African Neurosurgical Collaboration creates impact that lasts.

How do you build trust in a sector where progress takes years? Helena Strigård (Ventures Accelerated) shares key insights and explores the critical balance between transparency, risk, and long-term potential in early-stage life science investing.

From Southern California to Seattle, Ventures  Accelerated is set on a fast-paced expansion as they are establishing footholds in every major life science hub of the U.S. West Coast while appointing Roger Lias, Ph.D. as President of  its U.S. operations.

With roots in journalism at Reuters News in Hong Kong and a career spanning global health, biotech, and nonprofit advocacy, Alexandra Hoegberg is a master of message and mission. Her strategic communications work has influenced policy, built reputations, and connected stakeholders across borders and sectors. She is now a fierce entrepreneur and consultant – and recently joined the Ventures Accelerated team. 

Founder Helena Strigård interviews her on the driving force behind that sharp pen of hers! 

JPM Healthcare Week is no longer about being seen: it’s about being ready. In this piece, conversations with OnDosis and Treos Bio reveal how strategic clarity, credible data, and execution maturity now define meaningful engagement at JPM. From personalized drug delivery to globally aligned clinical development, the article highlights what it takes to show up with intent in today’s capital-constrained market.

In this Corporate Insights, Julie Ames, President and CEO of The Cambridge Group, argues that JP Morgan Healthcare Week is not about visibility, but reputation. Drawing on deep experience advising life science leaders, she explains how JPM has become a high-signal stress test where strategic clarity, disciplined storytelling, and leadership judgment matter more than volume or hype. The piece outlines how companies are evaluated before, during, and after the week, and why those that arrive prepared build momentum long after JPM ends.